A review on dendrimer-based nanoconjugates and their intracellular trafficking in cancer photodynamic therapy.
Lufuno NemakhavhaniAbrahamse HeidiSathish Sundar Dhilip KumarPublished in: Artificial cells, nanomedicine, and biotechnology (2024)
Nanotechnology-based cancer treatment has received considerable attention, and these treatments generally use drug-loaded nanoparticles (NPs) to target and destroy cancer cells. Nanotechnology combined with photodynamic therapy (PDT) has demonstrated positive outcomes in cancer therapy. Combining nanotechnology and PDT is effective in targeting metastatic cancer cells. Nanotechnology can also increase the effectiveness of PDT by targeting cells at a molecular level. Dendrimer-based nanoconjugates (DBNs) are highly stable and biocompatible, making them suitable for drug delivery applications. Moreover, the hyperbranched structures in DBNs have the capacity to load hydrophobic compounds, such as photosensitizers (PSs) and chemotherapy drugs, and deliver them efficiently to tumour cells. This review primarily focuses on DBNs and their potential applications in cancer treatment. We discuss the chemical design, mechanism of action, and targeting efficiency of DBNs in tumour metastasis, intracellular trafficking in cancer treatment, and DBNs' biocompatibility, biodegradability and clearance properties. Overall, this study will provide the most recent insights into the application of DBNs and PDT in cancer therapy.
Keyphrases
- photodynamic therapy
- cancer therapy
- drug delivery
- induced apoptosis
- fluorescence imaging
- cell cycle arrest
- drug release
- randomized controlled trial
- endoplasmic reticulum stress
- small cell lung cancer
- systematic review
- papillary thyroid
- working memory
- risk assessment
- high resolution
- radiation therapy
- metabolic syndrome
- young adults
- climate change
- locally advanced
- rectal cancer
- adipose tissue
- drug induced
- cell proliferation
- lymph node metastasis
- insulin resistance
- childhood cancer